Medicine and Dentistry
Hepatocellular Carcinoma
100%
Lenvatinib
100%
Bilirubin
78%
Albumin
78%
Overall Survival
59%
Progression Free Survival
54%
Bleeding
50%
Thrombectomy
50%
Computer Assisted Tomography
50%
Femoral Artery
50%
Systematic Review
50%
Odds Ratio
50%
Meta-Analysis
50%
Artery Puncture
50%
Survival Analysis
50%
Vein Puncture
33%
Neoplasm
32%
Retrospective Study
28%
Intermediate Risk Population
25%
High Risk Population
25%
Brain Ischemia
16%
Puncture
16%
Fluoroscopy
16%
Patient Population
16%
Randomized Controlled Trial
16%
Decision Making
16%
Alanine Aminotransferase
14%
Liver Function
13%
Proportional Hazards Model
11%
Odds Ratio
11%
Mechanical Thrombectomy
11%
Hazard Ratio
9%
Immunotherapy
9%
Prognostic Factor
7%
Clinician
7%
Effective Treatment
7%
Prospective Study
7%
Biological Marker
7%
Alpha-Fetoprotein
7%
Treatment Response
7%
Pharmacology, Toxicology and Pharmaceutical Science
Lenvatinib
100%
Liver Cell Carcinoma
100%
Bilirubin
78%
Albumin
78%
Overall Survival
59%
Progression Free Survival
54%
Neoplasm
32%
Alanine Aminotransferase
14%
Retrospective Study
11%
Immunotherapy
9%
Biological Marker
7%
Alpha Fetoprotein
7%
Prospective Study
7%
Biochemistry, Genetics and Molecular Biology
Progression Free Survival
50%
Overall Survival
50%
Albumin
28%
Bilirubin
28%
Intermediate Risk Population
21%
High Risk Population
21%
Alanine
14%
Transaminase
14%
Alpha-Fetoprotein
7%
Retrospective Study
7%
Prospective Study
7%